Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Nammi Therapeutics Inc. currently manages 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 6 distinct examiners, suggesting a decentralized review process where each case is handled by a different individual. The portfolio is active in 4 distinct art units, indicating a focused but varied technical scope within the biotechnology field that spans several specialized examination groups.
CABRAL, ROBERT S is identified as the busiest examiner for the company. This examiner is responsible for 1 pending office action. Given that there are 6 distinct examiners for 6 pending actions, the workload is evenly spread, with no single examiner managing a disproportionate share of the portfolio. This distribution requires a prosecution strategy that addresses the specific tendencies of 6 different examiners.
The presence of 6 distinct examiners across 4 distinct art units means that some art units likely contain multiple examiners working on the company's applications. This concentration within art units may provide opportunities for consistent group-level arguments, even while addressing the specific preferences of individual examiners. The 1 pending office action assigned to the busiest examiner reflects the current one-to-one ratio of examiners to pending matters in this portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (33%) |
| Double-patenting + other | 3 (50%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CABRAL, ROBERT S | 1 | 62.6% | +32.5% |
| DAVIS, BRIAN J | 1 | 84.8% | -4.0% |
| WEIDNER, ADAM M | 1 | 63.5% | +33.8% |
| WESTERBERG, NISSA M | 1 | 23.4% | +37.1% |
| STEINKE, SEAN JAMES | 1 | 12.5% | +42.9% |
| DENT, ALANA HARRIS | 1 | 44.2% | +32.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18831041 | Formulated and/or Co-Formulated Nanocarrier Compositions Containing TFGß Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | DAVIS, BRIAN J | 20d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18445604 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof C | WESTERBERG, NISSA M | 29d |
| 17803774 | Formulated and/or Co-Formulated Liposome Compositions Containing Immunogenic Cell Death (ICD) Inducing Prodrugs Useful In The Treatment of Cancer and Methods Thereof | STEINKE, SEAN JAMES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18445604 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof C | WESTERBERG, NISSA M | 29d |
| 18751742 | Formulated and/or Co-Formulated Liposome Compositions Containing PD-1 Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | CABRAL, ROBERT S | — |
| 18445651 | Fusion Protein Composition(s) Comprising Masked Type I Interferons (IFNa and IFNb) For Use in the Treatment of Cancer and Methods Thereof | WEIDNER, ADAM M | — |
| 17803774 | Formulated and/or Co-Formulated Liposome Compositions Containing Immunogenic Cell Death (ICD) Inducing Prodrugs Useful In The Treatment of Cancer and Methods Thereof | STEINKE, SEAN JAMES | — |
| 17803392 | Fusion Protein Composition(S) Comprising Masked Type I Interferons (IFNa and IFNß) For Use in the Treatment of Cancer and Methods Thereof | DENT, ALANA HARRIS | — |
| Art Unit | Apps |
|---|---|
| 1614 | 2 |
| 1618 | 1 |
| 1619 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18751742 | Formulated and/or Co-Formulated Liposome Compositions Containing PD-1 Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | CABRAL, ROBERT S | 1614 | §112 | Non-Final OA | — | Pending | Jun 24, 2024 |
| 18831041 | Formulated and/or Co-Formulated Nanocarrier Compositions Containing TFGß Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | DAVIS, BRIAN J | 1614 | §112 | Final Rejection | 20d | Pending | May 13, 2024 |
| 18445651 | Fusion Protein Composition(s) Comprising Masked Type I Interferons (IFNa and IFNb) For Use in the Treatment of Cancer and Methods Thereof | WEIDNER, ADAM M | — | §102§103DP | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18445604 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof C | WESTERBERG, NISSA M | 1618 | §103§112DP | Final Rejection | 29d | Pending | Nov 15, 2023 |
| 17803774 | Formulated and/or Co-Formulated Liposome Compositions Containing Immunogenic Cell Death (ICD) Inducing Prodrugs Useful In The Treatment of Cancer and Methods Thereof | STEINKE, SEAN JAMES | 1619 | §103§112 | Non-Final OA | — | Pending | Nov 17, 2022 |
| 17803392 | Fusion Protein Composition(S) Comprising Masked Type I Interferons (IFNa and IFNß) For Use in the Treatment of Cancer and Methods Thereof | DENT, ALANA HARRIS | 1643 | §102§112DP | Non-Final OA | — | Pending | Jun 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial